Suppr超能文献

纤维状肾小球肾炎或补体 3 肾小球病:弥漫性坏死性新月体肾小球肾炎伴 C3 优势性肾小球沉积和 DNAJB9 阳性的罕见病例。

Fibrillary glomerulonephritis or complement 3 glomerulopathy: a rare case of diffuse necrotising crescentic glomerulonephritis with C3-dominant glomerular deposition and positive DNAJB9.

机构信息

Division of Nephrology and Hypertension, Mayo Clinic Hospital Jacksonville, Jacksonville, Florida, USA.

Department of Pathology, Mayo Clinic Hospital Jacksonville, Jacksonville, Florida, USA.

出版信息

BMJ Case Rep. 2021 Feb 18;14(2):e239868. doi: 10.1136/bcr-2020-239868.

Abstract

Fibrillary glomerulonephritis (FGN) and complement 3 glomerulopathy (C3G) are rare forms of glomerulonephritis with distinct aetiologies. Both FGN and C3G can present with nephritic syndrome. FGN is associated with autoimmune disease, dysproteinaemia, malignancy and hepatitis C infection. C3G is caused by the unregulated activation of the alternative complement pathway. We present a rare case of diffuse necrotising crescentic glomerulonephritis with dominant C3 glomerular staining on immunofluorescence-consistent with C3G-but electron microscopy (EM) findings of randomly oriented fibrils with a mean diameter of 14 nm and positive immunohistochemistry for DNAJB9-suggestive of FGN. To the best of our knowledge, this is the first reported case of FGN to show dominant C3 glomerular deposits. This case report reaffirms the utility of EM in the evaluation of nephritic syndrome and highlights the value of DNAJB9-a novel biomarker with a sensitivity and specificity near 100% for FGN.

摘要

纤维状肾小球肾炎 (FGN) 和补体 3 肾小球病 (C3G) 是两种罕见的肾小球肾炎,具有不同的病因。FGN 和 C3G 均可表现为肾病综合征。FGN 与自身免疫性疾病、副蛋白血症、恶性肿瘤和丙型肝炎感染有关。C3G 是由替代补体途径的不受调节的激活引起的。我们报告了一例罕见的弥漫性坏死性新月体肾小球肾炎,免疫荧光表现为 C3 肾小球染色占优势,与 C3G 一致 - 但电子显微镜 (EM) 发现随机取向的纤维,平均直径为 14nm,并且 DNAJB9 的免疫组化阳性 - 提示 FGN。据我们所知,这是首例报告的表现为 C3 肾小球沉积优势的 FGN 病例。本病例报告再次证实了 EM 在评估肾病综合征中的实用性,并强调了 DNAJB9 的价值,这是一种新型生物标志物,对 FGN 的敏感性和特异性接近 100%。

相似文献

2
IgA-dominant glomerulonephritis with DNAJB9-negative fibrillar polytypic immunoglobulin deposits in the subepithelium.
CEN Case Rep. 2023 Aug;12(3):323-328. doi: 10.1007/s13730-022-00759-2. Epub 2022 Dec 28.
3
Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).
Kidney360. 2020 Jul 8;1(9):1002-1013. doi: 10.34067/KID.0002532020. eCollection 2020 Sep 24.
4
A case of juvenile-onset fibrillary glomerulonephritis diagnosed by mass spectrometry and immunohistochemistry of DNAJB9.
CEN Case Rep. 2022 Nov;11(4):412-416. doi: 10.1007/s13730-022-00693-3. Epub 2022 Feb 23.
6
DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN.
J Am Soc Nephrol. 2018 Jan;29(1):51-56. doi: 10.1681/ASN.2017030306. Epub 2017 Nov 2.
7
Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients.
Kidney Int. 2019 May;95(5):1269-1272. doi: 10.1016/j.kint.2019.01.024. Epub 2019 Mar 1.
8
Immunoglobulin-Negative DNAJB9-Associated Fibrillary Glomerulonephritis: A Report of 9 Cases.
Am J Kidney Dis. 2021 Mar;77(3):454-458. doi: 10.1053/j.ajkd.2020.04.015. Epub 2020 Jul 23.
10
DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.
Kidney Int Rep. 2017 Aug 8;3(1):56-64. doi: 10.1016/j.ekir.2017.07.017. eCollection 2018 Jan.

引用本文的文献

1
Fibrillary Glomerulonephritis, DNAJB9, and the Unfolded Protein Response.
Glomerular Dis. 2022 Jun 16;2(4):164-175. doi: 10.1159/000525542. eCollection 2022.
3
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities.
MedComm (2020). 2022 Aug 2;3(3):e161. doi: 10.1002/mco2.161. eCollection 2022 Sep.
4

本文引用的文献

1
Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).
Kidney360. 2020 Jul 8;1(9):1002-1013. doi: 10.34067/KID.0002532020. eCollection 2020 Sep 24.
2
Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort.
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1741-1750. doi: 10.2215/CJN.03870319. Epub 2019 Nov 4.
3
Fibrillary Glomerulonephritis: An Update.
Kidney Int Rep. 2019 Apr 29;4(7):917-922. doi: 10.1016/j.ekir.2019.04.013. eCollection 2019 Jul.
4
New developments in the diagnosis of fibrillary glomerulonephritis.
Kidney Int. 2019 Sep;96(3):581-592. doi: 10.1016/j.kint.2019.03.021. Epub 2019 Apr 9.
5
DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.
Kidney Int Rep. 2017 Aug 8;3(1):56-64. doi: 10.1016/j.ekir.2017.07.017. eCollection 2018 Jan.
6
Incidence and profile of C3 Glomerulopathy: A single center study.
Indian J Nephrol. 2015 Jan-Feb;25(1):8-11. doi: 10.4103/0971-4065.136889.
7
Current concepts in C3 glomerulopathy.
Indian J Nephrol. 2014 Nov;24(6):339-48. doi: 10.4103/0971-4065.134089.
8
C3 glomerulopathy: consensus report.
Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Epub 2013 Oct 30.
9
Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients.
Am J Kidney Dis. 2013 Oct;62(4):679-90. doi: 10.1053/j.ajkd.2013.03.031. Epub 2013 Jun 4.
10
Fibrillary glomerulonephritis: a report of 66 cases from a single institution.
Clin J Am Soc Nephrol. 2011 Apr;6(4):775-84. doi: 10.2215/CJN.08300910. Epub 2011 Mar 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验